PFGKX
Price
$35.23
Change
-$0.11 (-0.31%)
Updated
Jun 2 closing price
Net Assets
6.52B
RGAEX
Price
$87.32
Change
-$0.28 (-0.32%)
Updated
Jun 2 closing price
Net Assets
337.53B
Interact to see
Advertisement

PFGKX vs RGAEX

Header iconPFGKX vs RGAEX Comparison
Open Charts PFGKX vs RGAEXBanner chart's image
PFGKX vs RGAEX Comparison Chart in %
View a ticker or compare two or three
VS
PFGKX vs. RGAEX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PFGKX is a StrongBuy and RGAEX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGAEX has more cash in the bank: 338B vs. PFGKX (6.52B). RGAEX pays higher dividends than PFGKX: RGAEX (0.21) vs PFGKX (0.00). PFGKX was incepted earlier than RGAEX: PFGKX (13 years) vs RGAEX (24 years). PFGKX (0.67) is less costly to investors than RGAEX (0.63). RGAEX is a more actively managed with annual turnover of: 32.00 vs. PFGKX (26.00). PFGKX has a lower initial minimum investment than RGAEX: PFGKX (0) vs RGAEX (250). RGAEX annual gain was more profitable for investors over the last year : 14.83 vs. PFGKX (-1.26). RGAEX return over 5 years is better than : 24.89 vs. PFGKX (5.71).
PFGKXRGAEXPFGKX / RGAEX
Total Expense Ratio0.650.63103%
Annual Report Gross Expense Ratio0.670.63106%
Fund Existence13 years24 years-
Gain YTD5.05410.42548%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets6.52B338B2%
Annual Yield % from dividends0.000.21-
Returns for 1 year-1.2614.83-8%
Returns for 3 years26.4753.2050%
Returns for 5 years5.7124.8923%
Returns for 10 years91.92112.5282%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RIO111.672.71
+2.49%
Rio Tinto plc
BAYA12.300.10
+0.82%
Bayview Acquisition Corp
PSN60.840.18
+0.30%
Parsons Corp
IDT55.41-0.56
-1.00%
IDT Corp
LCTX1.21-0.05
-3.97%
Lineage Cell Therapeutics